SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus

Bernatsky, 2006, Mortality in systemic lupus erythematosus, Arthritis Rheum, 54, 2550, 10.1002/art.21955 Estudio EPISER. Prevalencia e impacto de las enfermedades reumáticas en la poblacion adulta española. Sociedad Española de Reumatología (Monografía). Merck, Sharp & Dohme, España, 2001. Ponticelli, 2010, Monoclonal antibodies for systemic lupus erythematosus, Pharmaceuticals, 3, 300, 10.3390/ph3010300 EMA. Ficha técnica de Belimumab. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002015/WC500110150.pdf%3E;%5B [accessed April 2012]. Ramos-Casals, 2010, Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases, Clin Exp Rheumatol, 28, 468 Fitch, 2011 2009 FitzGerald, 1999, Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients, Lupus, 8, 638, 10.1191/096120399680411443 Vitali, 1992, Clin Exp Rheumatol, 10, 541 Isenberg, 1989, Criteria for assessing disease activity in systemic lupus erythematosus, J Rheumatol, 16, 1395 Smolen, 1999, Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains, J Rheumatol, 26, 504 Bertsias, 2010, EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann Rheum Dis, 69, 2074, 10.1136/ard.2010.130476 Hawker, 1993, A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus, J Rheumatol, 20, 657 Arce-Salinas, 1996, Validity of retrospective disease activity assessment in systemic lupus erythematosus, J Rheumatol, 23, 846 Wollaston, 2004, Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group, J Rheumatol, 31, 2390 Nikpour, 2009, Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus, Arthritis Rheum, 61, 1152, 10.1002/art.24741 Petri, 2007, Disease activity assessment in SLE: do we have the right instruments?, Ann Rheum Dis, 66, iii61 Ruperto, 2011, International consensus for a definition of disease flare in lupus, Lupus, 20, 453, 10.1177/0961203310388445 Gladman, 2000, Accurately describing changes in disease activity in systemic lupus erythematosus, J Rheumatol, 27, 377 Petri, 2005, Combined oral contraceptives in women with systemic lupus erythematosus, N Engl J Med, 353, 2550, 10.1056/NEJMoa051135 Buyon, 2005, The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial, Ann Intern Med, 142, 953, 10.7326/0003-4819-142-12_Part_1-200506210-00004 Chambers, 2009, Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years, Rheumatology (Oxford), 48, 673, 10.1093/rheumatology/kep062 Ioannou, 2002, Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge, Postgrad Med J, 78, 599, 10.1136/pmj.78.924.599 King, 2007, Systemic lupus erythematosus: modern strategies for management: a moving target, Best Pract Res Clin Rheumatol, 21, 971, 10.1016/j.berh.2007.09.002 US Food and Drug Administration. Guidance for industry: systemic lupus erythematosus-developing medical products for treatment. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm [accessed 12.06.12]. Bertsias, 2009, EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints, Ann Rheum Dis, 68, 477, 10.1136/ard.2007.083030 Urowitz, 2012, Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort, Arthritis Care Res (Hoboken), 64, 132, 10.1002/acr.20648 Ruiz-Irastorza, 2009, Predictors of major infections in systemic lupus erythematosus, Arthritis Res Ther, 11, R109, 10.1186/ar2764 Urowitz, 2008, Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort, Arthritis Rheum, 59, 176, 10.1002/art.23353 Roman, 2003, Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus, N Engl J Med, 349, 2399, 10.1056/NEJMoa035471 2004, Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting, Arthritis Rheum, 50, 3427, 10.1002/art.20599 Gomez Reino, 2011, Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas, Reumatol Clin, 7, 284, 10.1016/j.reuma.2011.05.002 Baker, 2003, Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator, Arthritis Rheum, 48, 3253, 10.1002/art.11299 Halpern, 2006, Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects, Toxicol Sci, 91, 586, 10.1093/toxsci/kfj148 Moore, 1999, BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator, Science, 285, 260, 10.1126/science.285.5425.260 Cancro, 2009, The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus, J Clin Invest, 119, 1066, 10.1172/JCI38010 Cheema, 2001, Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, Arthritis Rheum, 44, 1313, 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S Zhang, 2001, Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus, J Immunol, 166, 6, 10.4049/jimmunol.166.1.6 Petri, 2008, Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus, Arthritis Rheum, 58, 2453, 10.1002/art.23678 Wallace, 2009, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus, Arthritis Rheum, 61, 1168, 10.1002/art.24699 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Furie, 2011, A phase iii, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, 63, 3918, 10.1002/art.30613 Dooley, 2011, Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus, Arthritis Rheum, 63, S963 Collins, 2011, Outcomes associated with belimumab in black/African American patients with systemic lupus erythematous in clinical practice settings in the United States [abstract], Arthritis Rheum, 64, 2617 Manzi, 2012, Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase iii trials, Ann Rheum Dis, 71, 1833, 10.1136/annrheumdis-2011-200831 Merrill, 2012, Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus, Arthritis Rheum, 64, 3364, 10.1002/art.34564 Merrill, 2010, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial, Arthritis Rheum, 62, 222, 10.1002/art.27233 Rovin, 2012, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study, Arthritis Rheum, 64, 1215, 10.1002/art.34359 Coca, 2012, Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome, Curr Opin Rheumatol, 24, 451, 10.1097/BOR.0b013e32835707e4 Furie, 2009, Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the Randomized, Double-Blind Phase III LUNAR Study, Arthritis Rheum, 60, S429 Furie, 2009, Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase iii lupus nephritis assessment with rituximab study (LUNAR), Ann Rheum Dis, 68, 253 Merrill, 2011, Assessment of flares in lupus patients enrolled in a phase ii/iii study of rituximab (EXPLORER), Lupus, 20, 709, 10.1177/0961203310395802 Garcia Hernandez, 2007, Rituximab for treatment of patients with systemic autoimmune diseases, Med Clin (Barc), 128, 458 Garcia-Hernandez, 2006, Experience with rituximab in the treatment of systemic erythematosus lupus, Reumatol Clin, 2, 23, 10.1016/S1699-258X(06)73016-9 Chen, 2011, Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study, Rheumatology (Oxford), 50, 1640, 10.1093/rheumatology/ker176 Li, 2009, Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?, Rheumatology (Oxford), 48, 892, 10.1093/rheumatology/kep124 Molloy, 2012, Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies, Arthritis Rheum, 64, 3043, 10.1002/art.34468 Terrier, 2010, Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry, Arthritis Rheum, 62, 2458, 10.1002/art.27541 Fernández-Nebro, 2012, Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study, Lupus, 21, 1063, 10.1177/0961203312446627 Vital, 2012, Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus, Rheumatology (Oxford), 51, 1131, 10.1093/rheumatology/kes042 Turner-Stokes, 2011, The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation, Rheumatology (Oxford), 50, 1401, 10.1093/rheumatology/ker018 Diaz-Lagares, 2012, Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts, Autoimmun Rev, 11, 357, 10.1016/j.autrev.2011.10.009 Murray, 2010, Off-label use of rituximab in systemic lupus erythematosus: a systematic review, Clin Rheumatol, 29, 707, 10.1007/s10067-010-1387-5 Sfikakis, 2005, Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future, Curr Opin Rheumatol, 17, 550, 10.1097/01.bor.0000172798.26249.fc Garcia-Carrasco, 2010, Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients, Lupus, 19, 213, 10.1177/0961203309351541 Tokunaga, 2007, Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system, Ann Rheum Dis, 66, 470, 10.1136/ard.2006.057885 Pinto, 2011, Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus, Lupus, 20, 1219, 10.1177/0961203311409273 Lindholm, 2008, Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus, J Rheumatol, 35, 826 Vesely, 2004, Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review, Ann Intern Med, 140, 112, 10.7326/0003-4819-140-3-200402030-00012 Ng, 2006, Repeated B cell depletion in treatment of refractory systemic lupus erythematosus, Ann Rheum Dis, 65, 942, 10.1136/ard.2005.044487 Grondal, 2000, Cytokine production, serum levels and disease activity in systemic lupus erythematosus, Clin Exp Rheumatol, 18, 565 Iwano, 1993, Urinary levels of IL-6 in patients with active lupus nephritis, Clin Nephrol, 40, 16 Linker-Israeli, 1991, Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis, J Immunol, 147, 117, 10.4049/jimmunol.147.1.117 ClinicalTrials.gov, 2012 ClinicalTrials.gov., 2012 Aringer, 2009, Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients, Rheumatology (Oxford), 48, 1451, 10.1093/rheumatology/kep270 Aringer, 2004, Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study, Arthritis Rheum, 50, 3161, 10.1002/art.20576 Uppal, 2009, Efficacy and safety of infliximab in active SLE: a pilot study, Lupus, 18, 690, 10.1177/0961203309102557 Matsumura, 2009, Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients, Clin Exp Rheumatol, 27, 416 Hayat, 2007, Safety and efficacy of infliximab in a patient with active WHO class iv lupus nephritis, Clin Rheumatol, 26, 973, 10.1007/s10067-006-0219-0 Ideguchi, 2007, Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab, Rheumatology (Oxford), 46, 1621, 10.1093/rheumatology/kem205 Hayat, 2007, Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus, Mod Rheumatol, 17, 174, 10.3109/s10165-006-0561-8 Kikuchi, 2012, Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus, Mod Rheumatol, 22, 308, 10.3109/s10165-011-0500-1 Micheloud, 2006, Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy, Lupus, 15, 881, 10.1177/0961203306070970 Takahashi, 2008, Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome, Mod Rheumatol, 18, 72, 10.3109/s10165-007-0006-z Atreya, 2000, Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo, Nat Med, 6, 583, 10.1038/75068 Najafian, 2000, CTLA4-Ig: a novel immunosuppressive agent, Expert Opin Investig Drugs, 9, 2147, 10.1517/13543784.9.9.2147 Merrill, 2010, The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase iib, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 3077, 10.1002/art.27601 Furie, 2011, Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase ii/iii study, Arthritis Rheum, 63, S971 Coca, 2009, Two negative randomized controlled trials in lupus: now what? F1000, Med Rep, 1, 28 Lateef, 2010, Biologics in the treatment of systemic lupus erythematosus, Curr Opin Rheumatol, 22, 504, 10.1097/BOR.0b013e32833b475e Wofsy, 2012, Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions, Arthritis Rheum, 64, 3660, 10.1002/art.34624 Nishimoto, 2008, Humanized antihuman IL-6 receptor antibody, tocilizumab, Handb Exp Pharmacol, 181, 151, 10.1007/978-3-540-73259-4_7 Chun, 2007, Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus, J Clin Immunol, 27, 461, 10.1007/s10875-007-9104-0 Peterson, 1996, Serum and urinary interleukin-6 in systemic lupus erythematosus, Lupus, 5, 571, 10.1177/096120339600500603 Mihara, 2005, The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody, Expert Opin Biol Ther, 5, 683, 10.1517/14712598.5.5.683 Shirota, 2005, The impact of in vivo anti IL-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus, Arthritis Rheum, 52, S697 Illei, 2010, Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study, Arthritis Rheum, 62, 542, 10.1002/art.27221 Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 Choy, 2002, Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial, Arthritis Rheum, 46, 3143, 10.1002/art.10623 Tedder, 1997, CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling, Annu Rev Immunol, 15, 481, 10.1146/annurev.immunol.15.1.481 Grammer, 2003, Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions, J Clin Invest, 112, 1506, 10.1172/JCI200319301 Kalunian, 2002, Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 3251, 10.1002/art.10681 Davis, 2001, Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus, J Rheumatol, 28, 95 Sidiropoulos, 2004, Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients, Lupus, 13, 391, 10.1191/0961203304lu1032oa Iwai, 2003, Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis, J Immunol, 171, 2848, 10.4049/jimmunol.171.6.2848 Llorente, 2000, Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus, Arthritis Rheum, 43, 1790, 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2 Lee, 2006, Type I interferon as a target of treatment in SLE, Endocr Metab Immune Disord Drug Targets, 6, 323, 10.2174/187153006779025702 Kalunian, 2012, Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study [abstract], Arthritis Rheum, 64, S1111 Rother, 2004, Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus, Lupus, 13, 328, 10.1191/0961203303lu1021oa Isenberg, 2005, BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus, Rheumatology (Oxford), 44, 902, 10.1093/rheumatology/keh624 Stoll, 1996, Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus, Ann Rheum Dis, 55, 756, 10.1136/ard.55.10.756 Hay, 1993, The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus, Q J Med, 86, 447 Isenberg, 2011, An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA, Ann Rheum Dis, 70, 54, 10.1136/ard.2010.132068 Symmons, 1988, Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG), Q J Med, 69, 927 Nasiri, 2010, Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic, Rheumatol Int, 30, 1605, 10.1007/s00296-009-1201-3 Yee, 2007, British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus, Arthritis Rheum, 56, 4113, 10.1002/art.23130 Ward, 2000, Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus, J Rheumatol, 27, 664 Yee, 2009, The BILAG-2004 index is sensitive to change for assessment of SLE disease activity, Rheumatology (Oxford), 48, 691, 10.1093/rheumatology/kep064 Mosca, 2000, The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus, Lupus, 9, 445, 10.1191/096120300678828640 Liang, 1989, Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus, Arthritis Rheum, 32, 1107, 10.1002/anr.1780320909 Bae, 2001, Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus, Lupus, 10, 405, 10.1191/096120301678646146 Gladman, 1994, Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation, J Rheumatol, 21, 1468 Fortin, 2000, Do lupus disease activity measures detect clinically important change?, J Rheumatol, 27, 1421 Gladman, 1992, Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus, J Rheumatol, 19, 608 Uribe, 2004, The Systemic lupus activity measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus, J Rheumatol, 31, 1934 Chang, 2002, Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians, J Clin Epidemiol, 55, 488, 10.1016/S0895-4356(01)00509-1 Bombardier, 1992, Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE, Arthritis Rheum, 35, 630, 10.1002/art.1780350606 Petri, 1992, Validity and reliability of lupus activity measures in the routine clinic setting, J Rheumatol, 19, 53 Gladman, 2002, Systemic lupus erythematosus disease activity index 2000, J Rheumatol, 29, 288 Guzman, 1992, Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices, J Rheumatol, 19, 1551 Yazdany, 2008, Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort, Arthritis Rheum, 59, 136, 10.1002/art.23238 Karlson, 2003, Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies, Lupus, 12, 280, 10.1191/0961203303lu332oa Gladman, 1996, The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus, Arthritis Rheum, 39, 363, 10.1002/art.1780390303 Stoll, 1996, SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus, Br J Rheumatol, 35, 248, 10.1093/rheumatology/35.3.248 Gladman, 2000, The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison, J Rheumatol, 27, 373 Gladman, 1997, The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus, Arthritis Rheum, 40, 809, 10.1002/art.1780400506 Stoll, 1997, Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus, J Rheumatol, 24, 309 Costenbader, 2010, Development and initial validation of a self-assessed lupus organ damage instrument, Arthritis Care Res (Hoboken), 62, 559, 10.1002/acr.20193 Fortin, 2008, Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 59, 1796, 10.1002/art.24068 Rahman, 1998, Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis, J Rheumatol, 25, 243 Chang, 2011, Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis, Arch Dermatol, 147, 1261, 10.1001/archdermatol.2011.191 Callen, 2005, Management of “refractory” skin disease in patients with lupus erythematosus, Best Pract Res Clin Rheumatol, 19, 767, 10.1016/j.berh.2005.05.003 Man, 2005, Serositis related to systemic lupus erythematosus: prevalence and outcome, Lupus, 14, 822, 10.1191/0961203305lu2187oa Appel, 2009, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis, J Am Soc Nephrol, 20, 1103, 10.1681/ASN.2008101028 Houssiau, 2010, Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial, Ann Rheum Dis, 69, 2083, 10.1136/ard.2010.131995 Houssiau, 2012, Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients, Arthritis Res Ther, 14, 202, 10.1186/ar3656 Houssiau, 2010, The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide, Ann Rheum Dis, 69, 61, 10.1136/ard.2008.102533 Dooley, 2011, Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis, N Engl J Med, 365, 1886, 10.1056/NEJMoa1014460 Hahn, 2012, American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care Res (Hoboken), 64, 797, 10.1002/acr.21664 Austin, 2009, Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy, J Am Soc Nephrol, 20, 901, 10.1681/ASN.2008060665 Postal, 2011, Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management, CNS Drugs, 25, 721, 10.2165/11591670-000000000-00000 Pego-Reigosa, 2009, Respiratory manifestations of systemic lupus erythematosus: old and new concepts, Best Pract Res Clin Rheumatol, 23, 469, 10.1016/j.berh.2009.01.002 Neunert, 2011, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, 117, 4190, 10.1182/blood-2010-08-302984 Provan, 2010, International consensus report on the investigation and management of primary immune thrombocytopenia, Blood, 115, 168, 10.1182/blood-2009-06-225565 Hepburn, 2010, The management of peripheral blood cytopenias in systemic lupus erythematosus, Rheumatology (Oxford), 49, 2243, 10.1093/rheumatology/keq269 Olivé, 2009, Manifestaciones hematológicas Dorner, 2006, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus, Arthritis Res Ther, 8, R74, 10.1186/ar1942 Daridon, 2010, Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus, Arthritis Res Ther, 12, R204, 10.1186/ar3179 2009 2010 Boumpas, 2003, A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis, Arthritis Rheum, 48, 719, 10.1002/art.10856 Yao, 2009, Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus, Arthritis Rheum, 60, 1785, 10.1002/art.24557 McBride JM, Morimoto A, Drappa J. Genentech's rontalizumab is well-tolerated by lupus patients in a phase i clinical trial. Lupus Foundation of America Website. Available from: http://www.lupus.org/webmodules/webarticlesnet/templates/new_empty.aspx?articleid=2844&zoneid=76 [accessed 03.06.12].